retatrutide expanded access compassionate use eli lilly PolitiFact Eli Lilly's experimental obesity drug

At the time of discontinuation, only 27 percent of those taking semaglutide for obesity had reached a dose of 1.7 mg or above

( Kennedy, D

Stick to smaller, frequent meals to optimize digestion and prevent nausea

It is a GLP-1 receptor agonist that helps: Control blood sugar levels (reduces HbA1c) Support weight loss (up to 8 kg in diabetic patients) Reduce hunger and appetite Protect heart and kidney health Lower risk of cardiovascular events Ozempic is approved by Indias drug regulator CDSCO in September 2025 and officially launched by Novo Nordisk in December 2025

doi: 10.1038/oncsis.2017.65 92 DaiEHanLLiuJXieYKroemerGKlionskyDJet al